GlassScriptPhysician profile
Adam Arnold Shpigel
NPI 1417223447
$34,469.19
in general payments reported to CMS, 2019-2025
38 companies · $2,686 in 2025
The $2,686 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $116 · 2021: $1,589 · 2022: $2,824 · 2023: $1,747 · 2024: $3,803 · 2025: $2,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,570 · Travel and Lodging: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,570.15 |
| Travel and Lodging | $1,665.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $19,694.46 | 2019-2020 | |
| Abbott Laboratories | $2,343.91 | 2019-2024 | Jot Dx, Mitraclip, Perclose Prostyle |
| Edwards Lifesciences Corporation | $2,108.60 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,782.86 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Comet |
| Abiomed | $1,192.53 | 2021-2025 | Impella |
| Amgen INC. | $963.58 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $930.78 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $825.96 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $778.83 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $567.58 | 2021-2024 | Symplicity G3, Linq II |
| Philips North America LLC | $436.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $375.23 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.76 | 2022-2025 | Jardiance |
| Chiesi USA, INC. | $296.81 | 2021-2025 | Kengreal, Cleviprex |
| Cardiovascular Systems INC. | $259.84 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $243.88 | 2021-2025 | Brilinta, Farxiga |
| Pfizer INC. | $224.82 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $126.47 | 2023-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $105.30 | 2022-2024 | Verquvo |
| Amarin Pharma, INC. | $103.88 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $88.22 | 2022-2025 | Amvuttra, Onpattro |
| Livanova USA, INC. | $68.47 | 2022 | |
| Scpharmaceuticals INC. | $61.57 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.38 | 2022-2024 | Eliquis, Camzyos |
| Cardiva Medical, INC. | $58.54 | 2024-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Inari Medical, INC. | $52.12 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lantheus Medical Imaging, INC. | $51.49 | 2021-2025 | |
| Heartflow, INC. | $47.64 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $43.00 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $40.67 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $38.10 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $28.94 | 2023 | Arcalyst |
| Biotronik INC. | $23.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.23 | 2023 | |
| Astellas Pharma US INC | $19.97 | 2021 | |
| Zoll Circulation INC | $17.65 | 2025 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Novo Nordisk INC | $15.64 | 2025 | Rybelsus, Ozempic |
| Cook Medical LLC | $12.91 | 2023 | Cook Celect |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Shpigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.